GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » Net-Net Working Capital

electroCore (electroCore) Net-Net Working Capital : $0.01 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is electroCore Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

electroCore's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.01.

The industry rank for electroCore's Net-Net Working Capital or its related term are showing as below:

ECOR's Price-to-Net-Net-Working-Capital is ranked worse than
98.66% of 448 companies
in the Medical Devices & Instruments industry
Industry Median: 6.405 vs ECOR: 675.00

electroCore Net-Net Working Capital Historical Data

The historical data trend for electroCore's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

electroCore Net-Net Working Capital Chart

electroCore Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial 6.88 4.86 6.26 2.39 0.55

electroCore Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 0.56 1.01 0.55 0.01

Competitive Comparison of electroCore's Net-Net Working Capital

For the Medical Devices subindustry, electroCore's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


electroCore's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, electroCore's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where electroCore's Price-to-Net-Net-Working-Capital falls into.



electroCore Net-Net Working Capital Calculation

electroCore's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(10.331+0.75 * 0.717+0.5 * 2.167-8.66
-0-0)/6.00263
=0.55

electroCore's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(7.849+0.75 * 0.475+0.5 * 2.507-9.394
-0-0)/6.00606
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


electroCore  (NAS:ECOR) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


electroCore Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of electroCore's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


electroCore (electroCore) Business Description

Traded in Other Exchanges
N/A
Address
200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.
Executives
Daniel S Goldberger director, officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Joseph P Errico director, 10 percent owner, officer: See Remarks 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Thomas J. Errico director, 10 percent owner 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
Trevor J Moody director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Julie Ann Goldstein director 205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber director 205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner officer: Chief Financial Officer 1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L director 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo director 10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033

electroCore (electroCore) Headlines

From GuruFocus